Phaseline

Companies › Sitala Bio

Sitala Bio: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Genitourinary, Ophthalmology; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
STL303–Phase 2IgAN; Geographic AtrophyJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07606352STL303Phase 2IgANGenitourinaryJul 2027
NCT07606365STL303Phase 2Geographic AtrophyOphthalmologyJul 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Vantage Biosciences Tioga Pharmaceuticals Tourmaline Bio, Inc., a Novartis Company Azure Biotech Sunhawk Vision Biotech

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.